Share
Market Research Report

ULCERATIVE COLITIS DRUG MARKET SIZE AND SHARE ANALYSIS - GROWTH TRENDS AND FORECASTS (2026-2033)

Segmentation
  • By Molecule TypeBiologics and Small Molecules
  • By Drug ClassAminosalicylates (Mesalamine (Asacol HD, Lialda), Olsalazin) · Corticosteroids (Budesonide (Uceris), Prednisone) · Anti-TNF Biologics (Infliximab (Remicade) Adalimumab (Humira)) · Integrin Receptor Antagonists · (Vedolizumab (Entyvio)) · Janus Kinase (JAK) Inhibitors · (Tofacitinib (Xeljanz), Upadacitinib (Rinvoq)) · Interleukin (IL)-12/23 Inhibitors · (Ustekinumab (Stelara), Risankizumab (Skyrizi)) · Sphingosine 1-Phosphate (S1P) Receptor Modulators · (Ozanimod (Zeposia), Etrasimod (Velsipity)) · Immunosuppressants · (Azathioprine, 6-Mercaptopurine) · Others
  • By Disease TypeUlcerative Proctitis · Left-Sided Colitis · Pancolitis · and Fulminant Colitis
  • By Disease SeverityMild Ulcerative Colitis · Moderate Ulcerative Colitis · and Severe Ulcerative Colitis
  • By Route of AdministrationOral · Parenteral · and Rectal
  • By Age GroupAdults · Pediatrics · and Geriatric
  • By GenderMale and Female
  • By Distribution ChannelHospital Pharmacies · Retail Pharmacies · and Online Pharmacies
  • By End UserHospitals and Clinics · Infusion Centers · Specialty Gastroenterology Clinics · Ambulatory Surgical Centers (ASCs) · Research and Diagnostic Laboratories · and Home Healthcare Settings
  • By GeographyNorth America · Europe · Asia Pacific · Latin America · Middle East · and Africa
  • Published In17 Mar 2026
  • Report CodeCMI8592
  • Pages250+
  • FormatsExcel and PDF
  • Base Year2025
  • Estimated Year2026
  • Historical Range2020 - 2024
  • Forecast Period2026-2033

Market Segmentation

  • Molecule Type Insights (Revenue, USD Bn, 2021 - 2033)

    • Biologics
    • Small Molecules
  • Drug Class Insights (Revenue, USD Bn, 2021 - 2033)

    • Aminosalicylates
      • Mesalamine (Asacol HD, Lialda)
      • Olsalazin
    • Corticosteroids
      • Budesonide (Uceris)
      • Prednisone
    • Anti-TNF Biologics
      • Infliximab (Remicade)
      • Adalimumab (Humira)
    • Integrin Receptor Antagonists
      • Vedolizumab (Entyvio)
    • Janus Kinase (JAK) Inhibitors
      • Tofacitinib (Xeljanz)
      • Upadacitinib (Rinvoq)
    • Interleukin (IL)-12/23 Inhibitors
      • Ustekinumab (Stelara)
      • Risankizumab (Skyrizi)
    • Sphingosine 1-Phosphate (S1P) Receptor Modulators
      • Ozanimod (Zeposia)
      • Etrasimod (Velsipity)
    • Immunosuppressants
      • Azathioprine
      • 6-Mercaptopurine
    • Others
  • Disease Type Insights (Revenue, USD Bn, 2021 - 2033)

    • Ulcerative Proctitis
    • Left-Sided Colitis
    • Pancolitis
    • Fulminant Colitis
  • Disease Severity Insights (Revenue, USD Bn, 2021 - 2033)

    • Mild Ulcerative Colitis
    • Moderate Ulcerative Colitis
    • Severe Ulcerative Colitis
  • Route of Administration Insights (Revenue, USD Bn, 2021 - 2033)

    • Oral
    • Parenteral
    • Rectal
  • Age Group Insights (Revenue, USD Bn, 2021 - 2033)

    • Adults
    • Pediatrics
    • Geriatric
  • Gender Insights (Revenue, USD Bn, 2021 - 2033)

    • Male
    • Female
  • Distribution Channel Insights (Revenue, USD Bn, 2021 - 2033)

    • Hospital Pharmacies
    • Retail Pharmacies
    • Online Pharmacies
  • End User Insights (Revenue, USD Bn, 2021 - 2033)

    • Hospitals and Clinics
    • Infusion Centers
    • Specialty Gastroenterology Clinics
    • Ambulatory Surgical Centers (ASCs)
    • Research and Diagnostic Laboratories
    • Home Healthcare Settings
  • Regional Insights (Revenue, USD Bn, 2021 - 2033)

    • North America
      • U.S.
      • Canada
    • Latin America
      • Brazil
      • Argentina
      • Mexico
      • Rest of Latin America
    • Europe
      • Germany
      • U.K.
      • Spain
      • France
      • Italy
      • Russia
      • Rest of Europe
    • Asia Pacific
      • China
      • India
      • Japan
      • Australia
      • South Korea
      • ASEAN
      • Rest of Asia Pacific
    • Middle East
      • GCC Countries
      • Israel
      • Rest of Middle East
    • Africa
      • South Africa
      • North Africa
      • Central Africa